Immunohistochemical and WB results revealed that the expressions of IRS‐1 and GSK3β in the AD group were both increased compared with those in the control group (*p < 0.05, **p < 0.01) and decreased after DSS treatment (**p < 0.01) (Figures 6C,D and 7B,G). This evidence concerns the gene GSK3B and Alzheimer disease.